EXPECTANCY OF LIFE AND INCIDENCE RATE OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS. 15 YEARS RETROSPECTIVE ANALYSIS
(Abstract release date: 05/19/16)
EHA Library. ESCALANTE BARRIGON F. 06/09/16; 134852; PB1952
Dr. FERNANDO ESCALANTE BARRIGON
Contributions
Contributions
Abstract
Abstract: PB1952
Type: Publication Only
Background
In the last decade we have assisted to an amazing improvement in the management and expectancy of life of Multiple Myeloma (MM) patients.
Past decade also shows us a new demographic data in our society: the increment of expectancy of life and an excellent performance status. New expensive but very effective antimyeloma (antiMM) agents are in the center of attention of Hematologic and Public Healthcare Systems.
Aims
We have analysed our data base and calculate incidence by sex, age and three 5-years periods of time at diagnosis and obtain tendencies to get ready for next decade of ageing people with best antimyeloma agents.
Methods
We retrospectively analysed the incidence of patients with new diagnostic of Multiple Myeloma (NDMM) from 1998 to 2012.
Then we divide the cohort in several groups: sex and age at diagnosis (3 groups) and three 5-year period of time (1998-2002, 2003-07 and 2008-12). Characteristics of patients:
n= 273.
Male/female: 170/103.
Median age at diagnosis: 74 years (Range: 39-100).
We don´t see differences in median age between that three 5-years periods.
We have calculated the incidence per 100000 inhab/year using census data of our Local Registry of Tumours of our Public Health Area. (Table 1)
Results
There were a constant increase of Annual Average Incidence of more than 10% in the 3 periods: 4.57 vs 5,12 (+12%) vs 6,15 (+34,6%). This increment was due to older patients more than younger one.
This young group accounts for a constantly near one quarter of all NDMM.
There were a constant incidence of about 16-18 per 100000/year NDMM in population over 65 y.
We don´t observe large differences between groups over and under 75 years.
Conclusion
We have observed a more than expected incidence of NDMM in our Public Health Area. Demographics of other Public Health Areas Average Annual Incidence were quite different to ours, because of ageing of population in our Area. A preliminary analysis of incidence of period of 2013-14 are similar to last 2008-2012 period.
Session topic: E-poster
Keyword(s): Epidemiology, Multiple myeloma
Type: Publication Only
Background
In the last decade we have assisted to an amazing improvement in the management and expectancy of life of Multiple Myeloma (MM) patients.
Past decade also shows us a new demographic data in our society: the increment of expectancy of life and an excellent performance status. New expensive but very effective antimyeloma (antiMM) agents are in the center of attention of Hematologic and Public Healthcare Systems.
Aims
We have analysed our data base and calculate incidence by sex, age and three 5-years periods of time at diagnosis and obtain tendencies to get ready for next decade of ageing people with best antimyeloma agents.
Methods
We retrospectively analysed the incidence of patients with new diagnostic of Multiple Myeloma (NDMM) from 1998 to 2012.
Then we divide the cohort in several groups: sex and age at diagnosis (3 groups) and three 5-year period of time (1998-2002, 2003-07 and 2008-12). Characteristics of patients:
n= 273.
Male/female: 170/103.
Median age at diagnosis: 74 years (Range: 39-100).
We don´t see differences in median age between that three 5-years periods.
We have calculated the incidence per 100000 inhab/year using census data of our Local Registry of Tumours of our Public Health Area. (Table 1)
Results
There were a constant increase of Annual Average Incidence of more than 10% in the 3 periods: 4.57 vs 5,12 (+12%) vs 6,15 (+34,6%). This increment was due to older patients more than younger one.
This young group accounts for a constantly near one quarter of all NDMM.
There were a constant incidence of about 16-18 per 100000/year NDMM in population over 65 y.
We don´t observe large differences between groups over and under 75 years.
Conclusion
We have observed a more than expected incidence of NDMM in our Public Health Area. Demographics of other Public Health Areas Average Annual Incidence were quite different to ours, because of ageing of population in our Area. A preliminary analysis of incidence of period of 2013-14 are similar to last 2008-2012 period.
Session topic: E-poster
Keyword(s): Epidemiology, Multiple myeloma
Abstract: PB1952
Type: Publication Only
Background
In the last decade we have assisted to an amazing improvement in the management and expectancy of life of Multiple Myeloma (MM) patients.
Past decade also shows us a new demographic data in our society: the increment of expectancy of life and an excellent performance status. New expensive but very effective antimyeloma (antiMM) agents are in the center of attention of Hematologic and Public Healthcare Systems.
Aims
We have analysed our data base and calculate incidence by sex, age and three 5-years periods of time at diagnosis and obtain tendencies to get ready for next decade of ageing people with best antimyeloma agents.
Methods
We retrospectively analysed the incidence of patients with new diagnostic of Multiple Myeloma (NDMM) from 1998 to 2012.
Then we divide the cohort in several groups: sex and age at diagnosis (3 groups) and three 5-year period of time (1998-2002, 2003-07 and 2008-12). Characteristics of patients:
n= 273.
Male/female: 170/103.
Median age at diagnosis: 74 years (Range: 39-100).
We don´t see differences in median age between that three 5-years periods.
We have calculated the incidence per 100000 inhab/year using census data of our Local Registry of Tumours of our Public Health Area. (Table 1)
Results
There were a constant increase of Annual Average Incidence of more than 10% in the 3 periods: 4.57 vs 5,12 (+12%) vs 6,15 (+34,6%). This increment was due to older patients more than younger one.
This young group accounts for a constantly near one quarter of all NDMM.
There were a constant incidence of about 16-18 per 100000/year NDMM in population over 65 y.
We don´t observe large differences between groups over and under 75 years.
Conclusion
We have observed a more than expected incidence of NDMM in our Public Health Area. Demographics of other Public Health Areas Average Annual Incidence were quite different to ours, because of ageing of population in our Area. A preliminary analysis of incidence of period of 2013-14 are similar to last 2008-2012 period.
Session topic: E-poster
Keyword(s): Epidemiology, Multiple myeloma
Type: Publication Only
Background
In the last decade we have assisted to an amazing improvement in the management and expectancy of life of Multiple Myeloma (MM) patients.
Past decade also shows us a new demographic data in our society: the increment of expectancy of life and an excellent performance status. New expensive but very effective antimyeloma (antiMM) agents are in the center of attention of Hematologic and Public Healthcare Systems.
Aims
We have analysed our data base and calculate incidence by sex, age and three 5-years periods of time at diagnosis and obtain tendencies to get ready for next decade of ageing people with best antimyeloma agents.
Methods
We retrospectively analysed the incidence of patients with new diagnostic of Multiple Myeloma (NDMM) from 1998 to 2012.
Then we divide the cohort in several groups: sex and age at diagnosis (3 groups) and three 5-year period of time (1998-2002, 2003-07 and 2008-12). Characteristics of patients:
n= 273.
Male/female: 170/103.
Median age at diagnosis: 74 years (Range: 39-100).
We don´t see differences in median age between that three 5-years periods.
We have calculated the incidence per 100000 inhab/year using census data of our Local Registry of Tumours of our Public Health Area. (Table 1)
Results
There were a constant increase of Annual Average Incidence of more than 10% in the 3 periods: 4.57 vs 5,12 (+12%) vs 6,15 (+34,6%). This increment was due to older patients more than younger one.
This young group accounts for a constantly near one quarter of all NDMM.
There were a constant incidence of about 16-18 per 100000/year NDMM in population over 65 y.
We don´t observe large differences between groups over and under 75 years.
Conclusion
We have observed a more than expected incidence of NDMM in our Public Health Area. Demographics of other Public Health Areas Average Annual Incidence were quite different to ours, because of ageing of population in our Area. A preliminary analysis of incidence of period of 2013-14 are similar to last 2008-2012 period.
Session topic: E-poster
Keyword(s): Epidemiology, Multiple myeloma
{{ help_message }}
{{filter}}